Interrogation of SLFN11 in pediatric sarcomas uncovers an unexpected biological role and a novel therapeutic approach to overcoming resistance to replicative stress
J. Gartrell, M. Mellado-Lagarde, N. Martinez, M. Clay, A. Bahrami, N. Sahr, A. Sykes, K. Blankenship, L. Hoffmann, J. Xie, H. P. Cho, N. Twarog, M. Connelly, K.-K. Yan, J. Yu, , A. Shelat
This study investigates SLFN11's role in pediatric sarcomas, finding it promotes tumor growth and resistance to DNA-damaging agents, which can be overcome by BCL-XL inhibition.
bioRxiv · Nov 5, 2020 · PreprintCancer Biology